Notice Number: NOT-CA-20-038
Release Date: March 18, 2020
First Available Due Date: May 15, 2020
Expiration Date: May 16, 2020
National Cancer Institute (NCI)
Risk-stratified cancer survivorship care tailors follow-up care based on the level of need of the survivor (e.g., risk for recurrence, subsequent malignancies, physical and/or psychosocial sequelae). This Notice of Special Interest informs current National Cancer Institute (NCI) grant awardees that the NCI is seeking supplement applications that develop and/or validate algorithms that categorize survivors into meaningful risk-stratified groups in order to inform appropriate follow-up care.
In 2019, there were an estimated 16.9 million cancer survivors in the United States (U.S.), and this number is projected to grow to over 26 million survivors by 2040. Unfortunately, it is anticipated that the exponential growth in the number of cancer survivors will not be matched by a proportional increase in the number and availability of oncology healthcare providers. Many survivors lack a clear pathway for care after cancer treatment, and often remain in oncology providers’ care for longer than is clinically necessary. To relieve the impending burden of survivorship care that is likely to increase in the near future, and to ensure that survivor needs are appropriately managed, new models of survivorship care are needed. Risk-stratified models of survivorship care, where follow-up care for survivors is tailored based on factors such as risk for adverse outcomes, risk for recurrence, and functional ability, offer a possible solution. For example, cancer survivors diagnosed with early stage disease who are at lower risk for such issues may benefit from care delivered in part by providers other than oncology specialists (e.g., Primary Care Providers, Advanced Practice Practitioners, nurse-led follow-up clinics). Conversely, survivors with higher levels of needs would benefit from more intense follow-up care delivered by specialist providers. Although risk-stratified survivorship care models have been partially implemented in other countries, there is currently no evidence-based algorithm that identifies low-, medium-, and high-risk survivors for risk stratified survivorship care in the U.S.
Through this Notice, NCI is indicating interest in supplement applications that propose methodological approaches to identify individuals within low-, medium-, and high-need groups in a risk-stratified survivorship care algorithm. This work will inform future development of risk-stratified care pathways based on developed algorithms. Applications will be asked to utilize existing parent study data alone or in conjunction with data from other sources (e.g., electronic medical records, cancer registry data, claims data).
Please note the following:
Administrative supplement applications are limited to currently funded projects supported by NCI. Individual(s) must hold an active eligible grant (R01, U01, R37, P01, U19, or UM1). For supplements to parent awards that include multiple PDs/PIs, the supplement may be requested by any or all of the PDs/PIs (in accordance with the existing leadership plan) and submitted by the awardee institution of the parent award.
Description of circumstances for which administrative supplements are available.
Application and Submission Information
Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.
Administrative Review Process:
NCI will conduct administrative reviews of applications submitted to this Notice and will support the most meritorious applications submitted for consideration, based upon availability of funds.
NCI staff will consider the ability of the proposed supplement activities to increase or preserve the parent award’s overall impact within the original scope of the award. Primary considerations include, but are not limited to, the following:
Additional selection factors include:
Please direct all inquiries to:
Michelle Mollica, Ph.D., M.P.H., R.N., O.C.N.
National Cancer Institute (NCI)
Lisa Gallicchio, Ph.D.
National Cancer Institute